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A B S T R A C T
Valproic acid (VPA) has been reported to cause cognitive decline and parkinsonism that are reversed
with cessation of medication. Common imaging ﬁndings among these reports demonstrate reversible
cortical pseudoatrophy and enlargement of the lateral ventricles. This case exempliﬁes these adverse
effects of VPAwhich can cause reversible neurological symptoms even in long-term treated patients and
can present as dementia syndromes such as normal pressure hydrocephalus.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.1. Introduction
Although VPA is generally considered a safe medication in the
elderly,1 there are previous reports of patients developing
reversible cognitive decline or reversible parkinsonism, often
both.2–22 Common imaging ﬁndings among these reports are
reversible cortical pseudoatrophy and enlargement of the lateral
ventricles.3,4,11,13,18,20,23 Here we describe an epilepsy patient
treated with VPA for 15 years who presented to a Memory
Disorders Clinic to be evaluated for normal pressure hydrocepha-
lus due to a cognitive decline, gait changes, urinary incontinence,
and ventriculomegaly on brain imaging. All clinical symptoms
were reversed with cessation of VPA.
2. Case report
A 65-year-old woman with a generalized seizure disorder
which began at age 25 presented to a Memory Disorders Clinic
complaining of confusion. Medical records from the time of
epilepsy diagnosis could not be obtained to further characterize
her seizure type. After her ﬁrst seizure she was treated with
phenytoin for two years and subsequently had trials of mono-
therapy with Phenobarbital and carbamazepine. Since valproic
acid (VPA) was initiated approximately at age 50 she has been* Corresponding author at: Banner Alzheimer’s Institute, Phoenix AZ, 901 E
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doi:10.1016/j.seizure.2011.02.009seizure-free with an average daily dose of 1 g. No attempts of VPA
discontinuation were made. At age 63, she gradually developed a
gait disturbance, urinary incontinence, and worsening cognitive
impairment that began affecting her normal functioning in her
occupational and personal life over a two year period. Formal
cognitive testing displayed signiﬁcantly impaired memory ability
as well as impaired executive function, visual perception, and a
markedly slowed speed of mental information processing with
intact language abilities. The remainder of her neurological
examination was normal except for a moderately slow wide-
based gait with bilateral outward foot rotation requiring use of a
walker.
Incidentally, the patient has a history of gradual hearing loss of
unknown etiology starting in her early 50s. Her mother and
maternal uncle also had a similar pattern of hearing loss. The same
maternal uncle has a ‘‘generalized seizure disorder’’ of unknown
etiology that started in his early 60s.
VPA blood levels were stable (78–85mg/mL) and within the
therapeutic range. An ammonia level was normal (30mmol/L). A
brain MRI revealed mild prominence of the lateral ventricles
concerning for normal pressure hydrocephalus, however signiﬁ-
cant sulcal atrophy was also observed. Given the apparent
dementia, urinary incontinence, gait changes, and an MRI
suggestive of enlarged ventricles, a workup for normal pressure
hydrocephalus was pursued. A large volume lumbar puncture
(29 mL of CSF was expressed) did not beneﬁt gait or cognitive
measures. During the procedure the patient developed a severe
positional headache. CSF studies were normal with no evidence of
infection or inﬂammation. CSF levels of Ab42 (491.4 pg/mL) and
phosphorylated-tau (32.35 pg/mL) were not consistent with
Alzheimer’s disease. An FDG PET scan revealed hypometabolismvier Ltd. All rights reserved.
Table 1
Ventricular measurements before and after cessation of VPA. Measure 1: transverse
diameter between lateralmost portions of the frontal horns of the lateral ventricles
at the level of the head of caudate by axial plane. Measure 2: transverse diameter of
frontal horns of the lateral ventricle by coronal plane at the level of the
hypothalamus. Measure 3: greatest anteroposterior diameter of the right lateral
ventricle by sagittal plane. Measure 4: greatest anteroposterior diameter of the left
lateral ventricle by sagittal plane.
Time of MRI (months) Measurement (mm)
1 2 3 4
57months prior 41.4 37.1 76.8 76.7
21months prior 42.1 41.3 80.3 79.7
7months prior 43.0 43.2 82.2 81.5
4months after 43.5 41.4 78.2 80.4
M.D. Evans et al. / Seizure 20 (2011) 509–511510in the bilateral periventricular regions, right anterior parietal
region, and few small scattered areas of decreased metabolic
activity in the right frontal region. This pattern is not consistent
with Alzheimer’s disease.
VPA was changed to levetiracetam without incident. Cogni-
tion and gait disturbance gradually normalized over the
following two months. A brain MRI 4 months after cessation of
VPA showed possible reduction of ventricular size (see Table 1).
On 3 out of 4 measures of ventricle size, numeric reductions were
seen 4 months after cessation of VPA. The ventricular measure-
ments were performed by a radiologist blinded to the clinical
history.
3. Discussion
Our patient gradually developed dementia symptoms and a gait
disturbance after 15 years of VPA use. About two months after
discontinuation of VPA, her cognition and gait returned to normal,
implicating a VPA-induced syndrome. Although she also presented
with urinary incontinence, it appears due to an unrelated urologic
disorder.
A possible mechanistic explanation involves inhibition of
neurite outgrowth. Using SY5Y neuroblastoma cells as a neuronal
model, Qian et al. found that therapeutic plasma levels of VPA
reduced cell proliferation and neurite outgrowth.24 VPA also
reduced mRNA and protein levels of neuroﬁlament 160 (NF160).
These effects were reversed after 2 days of cessation of VPA
exposure.
GABA pathway disturbance leading to dopamine inhibition has
also been hypothesized.16 Evidence indicates that GABA mediates
dopaminergic function in the substantia nigra.25 VPA or a
metabolite of VPA such as delta-2-valproate, which may be a
more potent inhibitor of the human brain GABA-degrading enzyme
than VPA,26 may cause a transient inhibitory effect on dopaminer-
gic pathways.
Another proposed mechanism of the reversible cognitive
decline seen in these patients taking VPA is a mitochondrial
DNA (mtDNA) mutation. Since VPA enters mitochondrial metabo-
lism pathways, a clinically silent mutation could become overt
when a new drug or drug metabolite is introduced.27 One of the
reported cases of VPA-induced non-hyperammonemic reversible
cognitive decline describes a pediatric patient who was found to
have a C8393TT-Pro!Ser mutation in the MTATP8 gene.3 Such a
mutation could explain the idiosyncratic nature of this drug side
effect. Also, since mtDNA mutations are heteroplasmic, it would
explain the highly variable clinical timeline of symptom appear-
ance.
It is possible that our patient’s hearing loss and epilepsy are all
related to an undiagnosed mtDNA mutation syndrome, which is
supported by the family history of idiopathic generalized seizures
and hearing loss that follows a pattern of maternal inheritance. Inour patient, genetic testing was not performed. VPA-induced
reversible sensorineural hearing loss has also been reported,28 but
cessation of VPA had no effect on hearing in our patient.
4. Conclusion
This case exempliﬁes the adverse effects of VPA, which can
cause neurological symptoms even in long-term treated patients.
Clinicians should be aware of how valproate-induced pseudoa-
trophy with cognitive impairment and parkinsonian features can
masquerade as dementia syndromes such as Alzheimer’s disease
or normal pressure hydrocephalus. Recognizing this clinical
scenario can allow clinicians to avoid unnecessary tests or
treatments, and most importantly, to possibly reverse the
condition.
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